Contact this trialFirst, we need to learn more about you.
GLP-1 Receptor Agonist
NNC0480-0389 +1 More for Type 2 Diabetes
Recruiting0 awardsPhase 2
Meridian, Idaho
This trial is testing a new combination therapy for type 2 diabetes, to see if it is more effective than current treatments. The study will last for 41 weeks, and participants will be given injections of either the new combination therapy or a placebo.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.